2019年末，在中國出現(xiàn)新型冠狀病毒（SARS-CoV-2）感染疾病，疫情的發(fā)展引起世界關(guān)注。中國舉國上下一直將防控疫情、保衛(wèi)人民生命安全作為全黨全國的第一要?jiǎng)?wù)。對病毒性疾病預(yù)防用疫苗和治療用藥物是重要組成部分，認(rèn)識這類藥物的研發(fā)難點(diǎn)，才有利于抗病毒藥物研發(fā)。綜述對SARS-CoV-2的認(rèn)識、反映中國科學(xué)家對新冠病毒肺炎的基礎(chǔ)研究貢獻(xiàn)，探討符合國家和國際技術(shù)規(guī)范的抗病毒藥物研發(fā)策略、藥物的篩選和研發(fā)及成藥性評價(jià)研究思路。

China's novel coronavirus (2019-nCoV) infection has attracted worldwide attention since the end of 2019. China has made the prevention and control of the epidemic and the protection of people's lives the top priority of the party and the country. Vac‐ cines for the prevention of viral diseases and drugs for treatment are important components. Understanding the difficulties in the de‐ velopment of these drugs is conducive to the development of antiviral drugs. This article reviews is the understanding the coronavi‐ rus (SARS-CoV-2), reflecting the contribution of Chinese scientists to the basic research of pneumonia, and discussing the develop‐ ment, screening and evaluation of antiviral drugs in line with national and international technical specifications.

R373